Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.

@article{Nicholson2004CombinationAA,
  title={Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.},
  author={Brian Nicholson and Kathryn M Gulding and Mark A Conaway and Stephen R. Wedge and Dan Theodorescu},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2004},
  volume={10 24},
  pages={8728-34}
}
PURPOSE Androgen ablation therapy leads to mild regression or stabilization of prostate cancer, followed by progression to the fatal androgen-independent state. Whereas androgen ablation diminishes tumor angiogenesis by suppressing vascular endothelial growth factor (VEGF) production, androgen-independent disease is marked by androgen-independent VEGF expression. We examined combined androgen ablation and inhibition of VEGF signaling in an androgen-sensitive human prostate cancer xenograft… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.

Clinical cancer research : an official journal of the American Association for Cancer Research • 1997
View 13 Excerpts
Highly Influenced

An extended Kaplan-Meier estimator and its applications.

Statistics in medicine • 1998
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…